Edgen Stock·Apr 01 2026, 03:08
(P1) Harmonicare (2256.HK) saw its shares jump over 5% after its cancer drug, Irpagratinib, received Orphan Drug Designation from the European Medicines Agency for treating hepatocellular carcinoma (HCC), the most common type of liver cancer.
(P2) "The ODD from the EMA is a significant milestone for Irpagratinib," the company said in a statement. "It provides strong support for the clinical development, registration, and commercialization of the product in Europe."
(P3) The designation is granted to drugs that treat rare, life-threatening, or chronically debilitating conditions affecting no more than five in 10,000 people in the EU. Irpagratinib, an oral small molecule inhibitor of FGFR4, is in clinical trials across multiple global sites. The stock rose 5.624% to HK$12.78 on the news.
(P4) The EMA's orphan status provides significant incentives, including 10 years of market exclusivity after approval, protocol assistance, and reduced regulatory fees. This could accelerate Irpagratinib's path to market and strengthen Harmonicare's oncology pipeline.
Hepatocellular carcinoma is a primary cancer of the liver and a leading cause of cancer-related deaths worldwide. The FGFR4 (Fibroblast Growth Factor Receptor 4) pathway is a key driver in a subset of HCC patients, making it a promising target for therapy.
Harmonicare's Irpagratinib (ABSK-011) is designed to be a highly selective inhibitor of this pathway, potentially offering a targeted treatment option for patients with this specific genetic mutation. The company has not yet disclosed the timeline for trial completion or submission for marketing authorization in Europe.
The EMA designation is a key validation of Irpagratinib's potential and de-risks its European regulatory path. Investors will now be closely watching for interim data from the ongoing clinical trials to assess the drug's efficacy and safety profile.
This article is for informational purposes only and does not constitute investment advice.
